Xtandi gains help push up Astellas revenues in fourth quarter

Headline results for the fourth quarter:

Revenue JPY 312.3 billion ($2.9 billion) +3.6
Sales JPY 5.4 billion ($50 million) -82.5%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

Astellas indicated that the impact of the COVID-19 pandemic on its financial results for fiscal 2019 have been "immaterial."

Other results:

  • Xtandi: JPY 102.1 billion ($955 million), up 28.1%, with the company noting that market penetration went fast than expected in earlier stages of prostate cancer
  • Prograf: JPY 46.7 billion ($ 436 million), up 2.2%, boosted by an increase in US demand due to a shortage of generic versions of the drug
  • Betanis, Myrbetriq and Betmiga: JPY 40.5 billion ($378 million), up 8.7%
  • Vesicare: JPY 8.6 billion ($80 million), down 58.4%
  • Xospata: JYP 4.5 billion ($42 million), up 137.4%, having launched in Europe last November following prior debuts in Japan and the US
  • US sales: $1 billion, up 12.4%
  • Japan sales: JPY 68.3 billion ($638 million), down 11.6%
  • Established markets sales: €650 million ($701 million), up 14.4%
  • International sales: JPY 32 billion ($299 million), up 13.8%
  • China, Taiwan and Hong Kong: JPY 16 billion ($149 million), down 7.8%
  • Full-year revenue: JPY 1.3 trillion ($12.2 billion), down 5.5% from the year prior
  • Full-year profit: JPY 195 billion ($1.8 billion), down 26.9% from the year prior

Looking ahead:

Astellas said that as "it is difficult to assess properly the impact [of COVID-19] on financial results at this point, the impact has not been incorporated" into its guidance for fiscal 2020. The Japanese drugmaker expects full-year sales of JPY 1.3 trillion ($12.1 billion) for fiscal 2020, down 1.4% from fiscal 2019, with profit of JPY 202 billion ($1.9 billion), which is 3.4% higher.

Pipeline updates:

The Japanese drugmaker disclosed that during the quarter, it discontinued Phase II trials of reldesemtiv in spinal muscular atrophy and in amyotrophic lateral sclerosis. It has also ended mid-stage trials of ASP4345 in cognitive impairment associated with schizophrenia, and of ASP0819 in fibromyalgia.  

To read more Top Story articles, click here.